Introduction
Methods
HTA agency and PE guideline search
Identification of CUA MAUI requirement or recommendation
Results
Guideline selection
Reason for exclusion | |||||
---|---|---|---|---|---|
National PE HTA not required for pricing, reimbursement or market access decision-making | No “official” published national PE HTA guidelines | CUA not required in PE HTA | Subnational guidelines only | Use multinational guidelines | |
Argentina | \(\checkmark\) | ||||
Austria | \(\checkmark\) | ||||
Baltic States | \(\checkmark^{\text a}\) | ||||
Germany | \(\checkmark\) | ||||
Italy | \(\checkmark\) | ||||
Kazakhstan | \(\checkmark\) | ||||
Romania | \(\checkmark\) | ||||
Spain | \(\checkmark\) | \(\checkmark\) | |||
Switzerland | \(\checkmark\) | \(\checkmark\) | |||
Tunisia | \(\checkmark\) | \(\checkmark\) | |||
United States | \(\checkmark\) | ||||
Uruguay | \(\checkmark\) | \(\checkmark^{\text b}\) |
Country | Agency | Guideline | Year | Recommended or preferred MAUI | Reason for preference | Notes/observations of relevance |
---|---|---|---|---|---|---|
Prefer/encourage use of a single MAUI | ||||||
Belgium | Belgian Health Care Knowledge Centre | Belgian Guidelines for Economic Evaluations and Budget Impact Analyses, 2nd Edition | 2012 | EQ-5D | “In order to stimulate the use of generic utility instruments and to promote consistency” | Use of Belgian preference values is preferred |
Bulgaria | National Center for Public Health and Analysis | Health Technology Assessment Guidelines | 2018 | EQ-5D-3L EQ-5D-5L | “…it [EQ-5D] is commonly used, it allows the greatest comparability of the results of economic analyses.” | |
Columbia | El Instituto de Evaluación Tecnológica en Salud (IETS) (Institute of Health Technology Assessment) | Manual Para la Elaboración de Evaluaciones Económicas en Salud (Manual for the Preparation of Economic Evaluations in Health) | 2014 | EQ-5D-3L | Not stated | Preferences from Latino population in USA should be used |
Croatia | Agency for Quality and Accreditation in Health Care | Croatian Guideline for Health Technology Assessment Process and Reporting | 2011 | EQ-5D | Not stated | National preferences required |
Czech Republic | Státní Ústav pro Kontrolu Léčiv (State Institute for Drug Control) | Cost-Effectiveness Analysis Critical Appraisal Procedure | 2017 | EQ-5D | “A pharmacoeconomic evaluation always has to apply the same method of measuring quality of life to all (clinical) conditions, as individual methods are not mutually comparable and result in varying partial values of utility.” | Preference to use Czech health preferences, but if not available, use utilities from the UK |
England | National Institute for Health and Care Excellence (NICE) | Guide to the Methods of Technology Appraisal (PMG9) NICE. Position Statement on Use of the EQ-5D-5L Valuation Set for England | 2013 2018 | EQ-5D-3L EQ-5D-5L | “Different methods used to measure health-related quality of life produce different utility values; therefore, results from different methods or instruments cannot always be compared. Given the need for consistency across appraisals, one measurement method, the EQ-5D, is preferred for the measurement of health-related quality of life in adults.” | Use UK 3L-value set with mapping if 5L descriptive system used |
The Netherlands | Zorginstituut Nederland | Dutch National Guideline for Economic Evaluations in Healthcare | 2016 | EQ-5D-5L | “In view of the possible differences in the assessment of quality of life that may arise from the use of different questionnaires, quality of life should consistently be measured with the EQ-5D-5L and should be valued using Dutch reference values.” | Use Dutch preference values |
New Zealand | Pharmaceutical Management Agency (PHARMAC) | Prescription for Pharmacoeconomic Analysis. Methods for Cost-Utility Analysis (Version 2.2) | 2015 | EQ-5D | “The EQ-5D is widely used internationally and utility weights have been derived from the New Zealand population. Therefore, PHARMAC recommends referring to the EQ-5D Tariff 2 first and using it to describe the health states.” | Use New Zealand Tariff 2 |
Norway | Norwegian Medicines Agency | Guidelines for the submission of documentation for single technology assessment of pharmaceuticals | 2018 | EQ-5D-3L EQ-5D-5L | “To make comparison between different single technology assessments possible, EQ-5D must, as a rule, be used.” | For consistency, the results from 3 and 5L should be converted to a comparable set of values (mapped to 3L values). The UK population-based tariff is recommended until a more relevant and applicable (Norwegian) tariff is available |
Poland | Agencja Oceny Technologii Medycznych (AOTMiT) (Agency for Health Technology Assessment and Tariff System) | Health Technology Assessment Guidelines (Version 3.0) | 2016 | EQ-5D-3L EQ-5D-5L | “…since it is commonly used, it allows for the greatest comparability of the results of economic analyses.” | Use Polish 3L value set and crosswalk until 5L value set is available |
Portugal | Ministério da Saúde | Portaria (Ordinance) no. 391/2019. Sumário: Aprova os princípios e a caraterização das Orientações Metodológicas para Estudos de Avaliação Económica de Tecnologias de Saúde | 2019 | EQ-5D-5L | Not stated | Use Portuguese tariffs |
Scotland | Scottish Medicines Consortium (SMC) | Guidance to Submitting Companies for Completion of New Product Assessment Form | 2019 | EQ-5D | “Given the comparative nature of the SMC’s work and the need for consistency across appraisals, the SMC would ideally wish that all appraisals used the same system.” | Guideline notes, EQ-5D appears to be the most appropriate choice in the UK |
Thailand | Health Intervention and Technology Assessment Program (HITAP), Ministry of Public Health | Guidelines for Health Technology Assessment in Thailand (Second Edition) | 2014 | EQ-5D-3La | “…due to the validity, reliability, responsiveness, feasibility and availability of the established value set for Thai population.” | Use Thai value set |
Preference for more than one MAUI | ||||||
Chile | Ministerio de Salud de Chile | Guía Metodológica para la Evaluación Económica de Intervenciones en Salud en Chile (Methodological Guide for the Economic Evaluation of Health Interventions in Chile) | 2013 | EQ-5D DALY | There is a Chilean social valuation of EQ-5D health states National researchers are familiar with DALYs following burden of disease studies in Chile | Chilean preferences used |
France | Haute Autorité de Santé (French National Authority for Health) | Choices in Methods for Economic Evaluation: A Methodological Guide | 2012 | EQ-5D HUI | “…in order to promote the consistency and comparability across CUAs. They are the only ones, to date, with a set of preferences values obtained from a representative sample of the French population.” | Use validated French preference values |
Country/region | Agency | Guideline | Year | MAUIs named as examples | Utility weights based on preferences of domestic population preferred |
---|---|---|---|---|---|
Australia | Pharmaceutical Benefits Advisory Committee, Department of Health and Ageing, Australian Government (PBAC) | Guidelines for Preparing a Submission to the Pharmaceutical Benefits Advisory Committee (Version 5.0) | 2016 | EQ-5D (3L and 5L) HUI2 or HUI3 SF-6D AQoL CHU9D | \(\checkmark\) |
Brazil | Ministério da Saúde | Diretrizes Metodológicas: Diretriz de Avaliação Econômica: 2nd Edition (Methodological Guideline: Economic Assessment Guideline) | 2014 | EQ5D SF-6D HUI QWB | \(\checkmark\) |
Canada | Canadian Agency for Drugs and Technologies in Health (CADTH) | Guidelines for the Economic Evaluation of Health Technologies: Canada (4th Edition) | 2017 | EQ-5D HUI SF-6D | \(\checkmark\) |
Cuba | Ministry of Health | Methodological Guidelines for Health Economic Evaluation in Healthcare | 2003 | Nonea | Not stated |
Egypt | Ministry of Health; Egyptian Drug Authority | Guidelines for Reporting Pharmacoeconomic Evaluations | 2013b | EQ-5D SF-6D | Unclearc |
Finland | Lääkkeiden hintalautakunta (Hila; Pharmaceuticals Pricing Board, Ministry of Social Affairs and Health) | Submission guideline: Preparing a health economic evaluation to be attached to the application for reimbursement status and wholesale price for a medicinal product | 2018 | None | Not stated |
Hungary | National institute for Pharmacy and Nutrition (OGYÉI) | Professional healthcare guideline on the methodology of health technology assessment | 2017 | EQ-5D SF-6D | \(\checkmark\) |
Irand | Iran Ministry of Health and Medical Education Iran Food and Drug Administration National committee for selecting and registering medicine | Regulation of Submitting Applications for Medicine with Regard to Development of Economic Evaluation | 2016 | EQ-5D SF-6D SF-36 | \(\checkmark\) |
Ireland | Health Information and Quality Authority | Guidelines for the Economic Evaluation of Health Technologies in Ireland | 2018 | EQ-5D (3L and 5L) SF-6D | \(\checkmark\) |
Israel | Ministry of Health – Pharmaceutical Administration | Guidelines for the submission of a request to include a pharmaceutical product in the national list of health services | 2010 | None | From a similar populatione |
Japan | Center for Outcomes Research and Economic Evaluation for Health, National Institute of Public Health (C2H) | Guideline for Preparing Cost-Effectiveness Evaluation to the Central Social Insurance Medical Council | 2019 | EQ-5D SF-6D HUI | \(\checkmark\) |
Malaysia | Ministry of Health | Pharmacoeconomic Guideline for Malaysia | 2012 | EQ-5D HUI3 SF-6D | \(\checkmark\) |
Mexicof | Consejo de Salubridad General | Guide for Conducting Economic Evaluation Studies for Updating the National Formulary in Mexico | 2017 | None | \(\checkmark\) |
Singapore | Agency for Care Effectiveness | Drug Evaluation Methods and Process Guide | 2018 | EQ-5D-5L SF-6D HUI3 AQoL | \(\checkmark\) |
Slovak republic | Ministry of Health | Metodická pomôcka pre vykonávanie farmako-ekonomického rozboru lieku, medicínsko-ekonomického rozboru zdravotníckej pomôcky a medicínsko-ekonomického rozboru dietetickej potraviny Decree no. 422/2011: Vyhláška Ministerstva zdravotníctva Slovenskej republiky o podrobnostiach farmako-ekonomického rozboru lieku | 2012 | EQ-5D HUI QWB | Not stated |
Slovenia | Health Insurance Institute of Slovenia | Rules of Reimbursement. Official Gazette of the Republic of Slovenia, No 35/2013 | 2013 | None | Not stated |
South Koreag | Health Insurance Review and Assessment Service (HIRA) | Guidelines for Economic Evaluation for Pharmaceuticals: Second Version | 2011 | EQ-5Dh HUI QWB | \(\checkmark\) |
Sweden | Dental and Pharmaceutical Benefits Agency (TLV) | Ändring i Tandvårds-och Läkemedelsförmånsverkets Allmänna Råd (TLVAR 2003:2) om Ekonomiska Utvärderinga (Change in the Dental and Drug Benefits Agency’s General Advice [TLVAR 2003: 2] on Financial Evaluations) | 2017 | EQ-5D | ✖i |
Taiwanj | Center for drug evaluation | Methodological guidelines for health technology assessment | 2014 | EQ-5D SF-6D HUI | \(\checkmark\) |